Discover our Antibody Libraries and what makes us different.
Previously, Ken served as Director, COO and General Counsel for BioN2, a Mars Inc. subsidiary; and earlier, as General Counsel and Secretary for L1 AgroSciences, a VC-funded start-up. Ken began his career in the lab, and then worked internationally as a patent and transactional attorney for 25 years, operating from New York City, Silicon Valley and London.
During his tenure as an attorney, Ken was involved in representing numerous start-up and emerging biopharma companies, in some cases also serving strategic and leadership roles.
Ken holds a J.D. from Fordham University School of Law in New York and an A.B in Biology from Colby College in Maine.
Andrew is a vocal proponent for the use of sequenced recombinant antibodies in research to improve reproducibility. He has frequently served as an expert witness in antibody patent cases involving some of the world’s best selling antibody drugs. Andrew has published over 130 peer-reviewed papers and is the inventor on numerous patents and patent applications.
Andrew holds a PhD from Cambridge University, where he studied under Nobel Laureate Cesar Milstein, the inventor of monoclonal antibodies, and also holds an MB BS (medical degree) from the University of London as well as a BA and MA from Oxford University.
Hans previously worked at Point B Capital on strategic financial advisory projects. He completed engagements for entities including Mars, MolsonCoors, the Seattle Cancer Care Alliance, Sutter Health, OncoCyte, the PolyClinic, BloodWorks Northwest, the Wisconsin Alumni Research Fund, and others. Prior to joining Point B Capital, he was a co-founder of Integra Ventures, a life science VC fund. He was also part of a founding management team for an agricultural biotechnology company that raised over $14 million of venture capital from an investor syndicate that included Venrock, Arch, Polaris and the Welcome Trust.
Hans has served on the boards of Clear Medical (acquired by Stericycle in 2011), Wellpartner (acquired by CVS Health in 2017) and C-SATS (acquired by Johnson & Johnson in 2018).
He has a Bachelor of Science in management from the U.S. Coast Guard Academy and earned his Master of Business Administration at the University of Colorado.
Before joining Specifica, she was Research Assistant Professor in Experimental Therapeutics at the University of New Mexico and Associate Member of the UNM Comprehensive Cancer Center.
Her long-time collaboration with Andrew Bradbury, our co-founder and CSO, dates back to 2009 when she joined his laboratory as a post-doctoral fellow at the Los Alamos National Laboratory, first, and as Senior Scientist at the New Mexico Consortium.
He is currently the Chief Operating Officer at DermBiont, a clinical stage microbiome company. Previously he has played leadership roles in young and startup companies including CFO at DermBiont, VP of Finance and Operations at Pellepharm, and VP of Business Development at Adagene. Before working with startup companies, Max was the head of the licensing division at Dyax Corp. He has negotiated and closed over 50 biotechnology transactions. He has also worked in Finance at Vertex Pharmaceuticals and Merck KGaA. Max started his career as a bench scientist at Vertex Pharmaceuticals.
He holds an MBA from the F.W. Olin School of Business, where he has also guest lectured, and holds an undergraduate degree from Bates College.
Before joining Specifica, Fortunato was an Assistant Research Professor in Experimental Therapeutics at the University of New Mexico in Albuquerque. Previously, he was a postdoctoral fellow in the laboratory of our co-founder Andrew Bradbury, at the Los Alamos National Laboratory. Fortunato has co-authored over 32 peer-reviewed scientific publications, and is the co-inventor on several patents and patent applications.
He holds a PhD in Molecular Medicine and a B.S. in Molecular Biology from the University of Trieste, Italy.
He brings over 8 years of experience in the development and characterization of therapeutic antibodies in academic and biotech environments. Within industry, he worked as an analytical chemist to characterize antibody-based products in a cGMP/GMP facility.
As a predoctoral trainee at the Spatiotemporal Modeling Center of New Mexico and Los Alamos National Labs, he incorporated both experimental and computational approaches to develop antibody-based products for treatment in leukemia.
Frank is a co-inventor of a patented antibody therapy that he recently adapted for use as a chimeric antigen receptor (CAR) T cell therapy in acute lymphoblastic leukemia. He holds a Ph.D. in Biomedical Science (University of New Mexico), an M.S. in Molecular & Cell Biology (San Diego State) and a B.S. in Molecular Biology (Cal Poly, San Luis Obispo).
Andre is a pharmacist and a PhD in Biochemistry, degrees conferred by the University of Sao Paulo (Brazil). He has experience in the design and engineering of phage display libraries, and also on software development for the analysis of large datasets generated by next-generation sequencing.
His main research focus was always protein-protein interactions, having worked and authored papers related to the subject in the fields of computational chemistry, neglected diseases and cancer. He was awarded three fellowships from the Sao Paulo Research Foundation during his scientific training.
Andre was a founder and served as president of the non-profit pharmaceutical consulting company of the Pharmacy School of the University of Sao Paulo.
Camila is a chemist and a PhD in Biochemistry, degrees conferred by the University of Sao Paulo (Brazil). She has extensive research experience in cell-based assays, flow cytometry, fluorescent activated cell sorting and CRISPR/Cas9 genome engineering.
Camila managed a GMP facility for human pancreas processing into islets for diabetes treatment, implemented pre-clinical trial protocols and designed a biomaterial for cell encapsulation, aiming to avoid immunosuppression and to attenuate host post transplantation immune response. During her scientific training, she was awarded two fellowships from the Sao Paulo Research Foundation and three honorable mentions at scientific conferences.
Camila also worked in the pharmaceutical industry developing and conducting biological assays to evaluate the potency and stability of new biological drugs, according to international pharmacopoeial specifications.
A long time resident of Northern California, and a happy newcomer to Santa Fe, Kelly’s experience ranges from entrepreneurial ventures in property development and management, to residential real estate sales and marketing.
Kelly holds a BA degree in Political Science from the University of California Santa Barbara.
He also has over a decade of experience in commercial and residential construction working in the field as well as project management.
Prior to joining Specifica, Andy was the Lab Facilities and Operations Director for Pebble Labs. There he oversaw laboratory and facilities operations for many different research groups ranging in fields from fermentation and microbiology to plant biology and entomology.
She has extensive knowledge of soil microbes, the communities they construct, and statistical approaches to investigate those communities.
Genetics and bioinformatics have always been her primary research interests. As those research interests have expanded, so has her experience in programming, mathematics, molecular biology, and virology. Prior to joining Specifica, she designed and ran entry level biology labs at New Mexico Tech as a teaching assistant.